UK Markets closed
  • FTSE 100

    5,860.28
    +74.63 (+1.29%)
     
  • FTSE 250

    18,109.57
    +215.15 (+1.20%)
     
  • AIM

    980.45
    +11.44 (+1.18%)
     
  • GBP/EUR

    1.0988
    -0.0074 (-0.67%)
     
  • GBP/USD

    1.3038
    -0.0042 (-0.3207%)
     
  • BTC-GBP

    10,054.18
    +9.69 (+0.10%)
     
  • CMC Crypto 200

    260.05
    -1.40 (-0.54%)
     
  • S&P 500

    3,465.39
    +11.90 (+0.34%)
     
  • DOW

    28,335.57
    -28.09 (-0.10%)
     
  • CRUDE OIL

    39.78
    -0.86 (-2.12%)
     
  • GOLD FUTURES

    1,903.40
    -1.20 (-0.06%)
     
  • NIKKEI 225

    23,516.59
    +42.32 (+0.18%)
     
  • HANG SENG

    24,918.78
    +132.65 (+0.54%)
     
  • DAX

    12,645.75
    +102.69 (+0.82%)
     
  • CAC 40

    4,909.64
    +58.26 (+1.20%)
     

Integumen PLC: Unveiling of new breath test/dig'l health platform

Integumen PLC
·2-min read

Unveiling of new COVID-19 personalised real-time Breath Test and Digital Health Pass Platform

COVID-19 wastewater Microtox ready for beta testing

Heads of Agreement with Avacta and Aptamer Group for commercial scale supply of SARS-CoV-2 binding agents

YORK, England, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Integumen today announces progress for its COVID-19 wastewater detection system, Microtox PD, in collaboration with Modern Water plc ("Modern Water"), Avacta Group plc ("Avacta") and Aptamer Group Limited ("Aptamer"). The Company also today announces the unveiling of a new personalised COVID-19 breath test, Microtox BT, and its complementary Digital Health Pass platform.

Integumen is working with a consortium of companies collaborating to find solutions in the fight against COVID-19 pandemic. The consortium includes Modern Water, Avacta, Aptamer and a major global provider of innovative technology and services for the data era.

Microtox BT and Digital Health Pass - on the spot triaging of COVID-19 infections offer potential to re-open the economy
Integumen recognised that in collaboration with Modern Water, Avacta and Aptamer Group, its real-time detection and alert system could be adapted to detect the level of infection of coronavirus in a breath sample. Adapting the wastewater test, Microtox PD, the Company has designed, built and tested a prototype, Microtox BT, which can analyse the breath and detect the spike protein of SARS-CoV-2 in real-time for those with a high viral load. Microtox BT has undergone extensive internal testing and will now transition to the University of Aberdeen containment level 3 laboratory, to undergo tests directly on the virus followed by a joint trial of up to 5,000 participants in parallel with third parties using reverse transcription polymerase chain reaction ("rtPCR")[i] and Antigen tests. Results are anticipated before the end of the year and Microtox BT is expected to be a Class 1 medical device[ii].

Click on, or paste the following link into your web browser, to view the associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/9879Z_1-2020-9-24.pdf

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

AIM share code: SKIN